Form 4: Repligen CEO Olivier Loeillot Reports Stock and Option Awards
SEC Form 4 Filing
Repligen's CEO, Olivier Loeillot, reports the acquisition of restricted stock units and stock options, according to a Form 4 filing with the SEC.
Summary
- Olivier Loeillot, CEO of Repligen Corporation, filed a Form 4 with the SEC.
- The filing reports the acquisition of 14,480 restricted stock units (RSUs) on March 3, 2025, at a price of $0.
- These RSUs vest in equal annual installments over three years, starting March 3, 2026.
- The filing also reports the acquisition of 13,627 stock options with an exercise price of $155.38 on March 3, 2025.
- These options vest in three equal annual installments starting March 3, 2026, and expire on March 3, 2035.
- Following these transactions, Mr. Loeillot beneficially owns 46,693 shares of common stock and 13,627 stock options.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, indicating confidence in the company's future performance.
Positives
- The grant of restricted stock units and stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.
Industry Context
This type of equity compensation is common in the biotech industry to incentivize and retain key executives.
Comparison to Industry Standards
- Equity grants are a standard component of executive compensation packages in the biotechnology industry.
- Companies like Danaher, Thermo Fisher Scientific, and Sartorius also utilize stock options and restricted stock units to align executive incentives with shareholder value.
- The vesting schedules are typical, with three-year vesting being a common practice.
Stakeholder Impact
- The equity grants align management's interests with shareholders, potentially driving long-term value creation.
- Employees may view the grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of transaction: Grant of restricted stock units and stock options. |
| 03/03/2026 | First vesting date for both restricted stock units and stock options. |
| 03/03/2027 | Second vesting date for both restricted stock units and stock options. |
| 03/03/2028 | Third vesting date for both restricted stock units and stock options. |
| 03/03/2035 | Expiration date for the stock options. |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.